Related Experiment Video
Updated: Feb 13, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
Published on: September 16, 2020
Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study
David Morrison1, James Shaffer2, Gui-Shuang Ying2
1Vanderbilt University Medical Center, Nashville Tennessee.
Insights
Treatment for retinopathy of prematurity (ROP) using laser or intravitreal bevacizumab (IVB) has very low complication rates. However, about 9% of laser-treated eyes experienced disease progression after ROP treatment.
Area of Science:
- Ophthalmology
- Neonatal Care
- Medical Research
Background:
- Retinopathy of prematurity (ROP) is a leading cause of visual impairment in premature infants.
- Effective treatment is crucial to prevent severe vision loss.
Purpose of the Study:
- To assess the frequency of ocular complications and disease progression after ROP treatment.
- To compare outcomes between laser therapy and intravitreal bevacizumab (IVB).
Main Methods:
- Retrospective cohort study of 1,004 eyes treated for ROP across 29 North American NICUs.
- Data abstracted from medical records up to 15 months post-treatment.
- Complications and disease progression categorized by treatment modality (laser vs. IVB).
Main Results:
- Overall complication rates were low: 2.6% for laser-treated eyes and 0% for IVB-treated eyes.
- Disease progression occurred in 9.2% of laser-treated eyes versus 0% of IVB-treated eyes.
- Vitreous hemorrhage occurred in 5.4% of laser-treated eyes.
Conclusions:
- ROP treatment with laser or IVB demonstrates a low incidence of ocular complications.
- A significant proportion of eyes treated with laser (9%) showed disease progression post-therapy.
- IVB appears to have a favorable safety profile with no observed complications or progression in this cohort.
Purpose:
To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP).
Methods:
This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression.
Results:
Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes.
Conclusions:
Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Pneumonia III: Complications and Assessment
Diabetes: Symptoms, Diagnosis, and Complications
Asthma-III: Symptoms and Complications
Classification of Asthma
Population Growth
Meristems and Plant Growth

